Dorthe da Graça Thrige
Profile
Dorthe da Graça Thrige worked as Chief Operating Officer at Ascelia Pharma AB from 2012 to 2019.
Prior to that, she held positions as Director-Development at Active Biotech AB, Vice President-Clinical & Regulatory Affairs at CMC Contrast AB, and Head-Drug Discovery at AstraZeneca AB.
She received a graduate and doctorate degree from the University of Copenhagen.
Former positions of Dorthe da Graça Thrige
Companies | Position | End |
---|---|---|
ASCELIA PHARMA AB | Chief Operating Officer | 30/12/2019 |
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Corporate Officer/Principal | - |
ACTIVE BIOTECH AB | Corporate Officer/Principal | - |
CMC Contrast AB
CMC Contrast AB Pharmaceuticals: MajorHealth Technology CMC Contrast AB develops magnetic resonance contrast agents for patients suffering with tumors. Its product CMC 001 is a Manganese containing orally administered magnetic resonance imaging (MRI) contrast medium for enhancement of the liver, bile ducts and gastrointestinal tract. The company was founded by Henrik S. Thomsen in 2000 and is headquartered in Malmo, Sweden. | Chief Tech/Sci/R&D Officer | - |
Training of Dorthe da Graça Thrige
University of Copenhagen | Doctorate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
ASCELIA PHARMA AB | Health Technology |
ACTIVE BIOTECH AB | Health Technology |
Private companies | 2 |
---|---|
CMC Contrast AB
CMC Contrast AB Pharmaceuticals: MajorHealth Technology CMC Contrast AB develops magnetic resonance contrast agents for patients suffering with tumors. Its product CMC 001 is a Manganese containing orally administered magnetic resonance imaging (MRI) contrast medium for enhancement of the liver, bile ducts and gastrointestinal tract. The company was founded by Henrik S. Thomsen in 2000 and is headquartered in Malmo, Sweden. | Health Technology |
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Commercial Services |
- Stock Market
- Insiders
- Dorthe da Graça Thrige